FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 17, 2023 -- The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate cancer.
The approval makes Akeega the first and only dual action tablet combining a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor with abiraterone acetate, given with prednisone.
The FDA approval is based on positive results from the randomized multicenter phase 3 MAGNITUDE study. Patients treated with the combination of Akeega plus prednisone had a statistically significant risk reduction in radiographic progression-free survival (rPFS). At a median follow-up of 24.8 months at the second interim analysis, rPFS, as adjudicated by central review, demonstrated a consistent trend favoring Akeega plus prednisone, with a median rPFS of 19.5 months versus 10.9 months for placebo and abiraterone acetate plus prednisone (AAP). There was also improvement seen in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy for Akeega plus prednisone versus AAP alone. There was also a trend observed toward improvement in overall survival.
"As a physician, identifying patients with a worse prognosis is a priority, especially those whose cancers have a BRCA mutation," Kim Chi, M.D., the principal investigator of the phase 3 MAGNITUDE study, said in a statement. "We prospectively designed the MAGNITUDE study to identify the subset of patients most likely to benefit from targeted treatment with Akeega and to help us understand how we can potentially achieve better health outcomes for patients."
Approval of Akeega was granted to Janssen.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Urine Test Might Help Men Skip Prostate Biopsies
THURSDAY, April 18, 2024 -- When prostate cancer strikes, one question is paramount: Is it aggressive and requiring immediate treatment, or slow-growing and worthy of monitoring...
Helping Poorer Patients Pay for Prostate Cancer Meds Keeps Them on Treatment
MONDAY, March 25, 2024 — Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than...
Ultrasound Plus MRI Could Be New Treatment Strategy Against Prostate Cancer
WEDNESDAY, March 20, 2024 -- Precisely delivered ultrasound could be an effective treatment for prostate cancer, with high-frequency sound waves heating and killing off cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
